Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II sunitinib in extensive-stage or sensitive-relapse small cell lung cancer
2006-002485-19Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sunitinib in small cell lung cancer (SCLC) (2 cohorts), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Disease control rate at 8 weeks. Started Sep 2008; status: terminated.
02
Drugs
sunitinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2006-002485-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002485-19.